Expert insight into the diagnostic markers and challenges of BPDCN, including the importance of involving dermatologists and pathologists, to identify various disease presentations in both adult and pediatric patients.
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More